Market open
Equillium/$EQ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Equillium
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Ticker
$EQ
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
35
ISIN
US29446K1060
Website
Equillium Metrics
BasicAdvanced
$14M
-
-$0.23
1.86
-
Price and volume
Market cap
$14M
Beta
1.86
52-week high
$0.87
52-week low
$0.34
Average daily volume
93K
Financial strength
Current ratio
3.93
Quick ratio
3.732
Long term debt to equity
0.981
Total debt to equity
2.015
Management effectiveness
Return on assets (TTM)
-13.58%
Return on equity (TTM)
-38.75%
Valuation
Price to revenue (TTM)
0.329
Price to book
0.71
Price to tangible book (TTM)
0.71
Price to free cash flow (TTM)
-0.707
Growth
Revenue change (TTM)
13.89%
Earnings per share change (TTM)
-40.59%
3-year earnings per share growth (CAGR)
-44.79%
Equillium News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Equillium stock?
Equillium (EQ) has a market cap of $14M as of May 14, 2025.
What is the P/E ratio for Equillium stock?
The price to earnings (P/E) ratio for Equillium (EQ) stock is 0 as of May 14, 2025.
Does Equillium stock pay dividends?
No, Equillium (EQ) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next Equillium dividend payment date?
Equillium (EQ) stock does not pay dividends to its shareholders.
What is the beta indicator for Equillium?
Equillium (EQ) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.